Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Recombinant human granulocyte- colony stimulating factor in women with unexplained recurrent pregnancy losses: a randomized clinical trial.

Eapen A, Joing M, Kwon P, Tong J, Maneta E, De Santo C, Mussai F, Lissauer D, Carter D; RESPONSE study group .

Hum Reprod. 2019 Mar 1;34(3):424-432. doi: 10.1093/humrep/dey393.

2.

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.

Craddock C, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, Brock K, Cavenagh J, Ingram W, Dennis M, Malladi R, Siddique S, Mussai F, Yap C.

J Clin Oncol. 2019 Mar 1;37(7):580-588. doi: 10.1200/JCO.18.00889. Epub 2019 Jan 17.

PMID:
30653424
3.

Haemophagocytic Lymphohistiocytosis Associated With 2 Cases of Pediatric Lymphocyte-depleted Classic Hodgkin Lymphoma.

Cader FZ, Colmenero I, Mussai F.

J Pediatr Hematol Oncol. 2018 Dec 27. doi: 10.1097/MPH.0000000000001398. [Epub ahead of print]

PMID:
30601404
4.

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, Vardon A, McConville CM, Cheng PN, Norris MD, Etchevers HC, Murray J, Ziegler DS, Chesler L, Schmidt R, Burchill SA, Haber M, De Santo C, Mussai F.

Cancer Res. 2019 Feb 1;79(3):611-624. doi: 10.1158/0008-5472.CAN-18-2139. Epub 2018 Dec 13.

PMID:
30545920
5.

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy.

Bokori-Brown M, Metz J, Petrov PG, Mussai F, De Santo C, Smart NJ, Saunders S, Knight B, Pastan I, Titball RW, Winlove CP.

Front Oncol. 2018 Nov 27;8:553. doi: 10.3389/fonc.2018.00553. eCollection 2018.

6.

Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.

Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, Perry T, Kearns P, Cheng P, Keeshan K, Craddock C, De Santo C.

Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32028. [Epub ahead of print]

PMID:
30485425
7.

Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.

De Santo C, Cheng P, Beggs A, Egan S, Bessudo A, Mussai F.

J Hematol Oncol. 2018 May 18;11(1):68. doi: 10.1186/s13045-018-0612-6.

8.

Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients.

Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, Yuan C, Morrow B, Zhang J, Korangy F, Greten TF, Steinberg SM, Stetler-Stevenson M, Middleton G, De Santo C, Hassan R.

Clin Cancer Res. 2018 Jun 15;24(12):2859-2872. doi: 10.1158/1078-0432.CCR-17-3757. Epub 2018 Mar 30.

PMID:
29602801
9.

Enteroviral Encephalitis in a Child With CNS Relapse of Burkitt Leukemia Treated With Rituximab.

Shaheen N, Mussai F.

J Pediatr Hematol Oncol. 2019 Jan;41(1):e27-e29. doi: 10.1097/MPH.0000000000001077.

PMID:
29315142
10.

The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.

De Santo C, Booth S, Vardon A, Cousins A, Tubb V, Perry T, Noyvert B, Beggs A, Ng M, Halsey C, Kearns P, Cheng P, Mussai F.

Int J Cancer. 2018 Apr 1;142(7):1490-1502. doi: 10.1002/ijc.31170. Epub 2017 Dec 26.

11.

Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.

Vardon A, Dandapani M, Cheng D, Cheng P, De Santo C, Mussai F.

Oncotarget. 2017 Jun 29;8(38):63506-63517. doi: 10.18632/oncotarget.18843. eCollection 2017 Sep 8.

12.

The development of targeted new agents to improve the outcome for children with leukemia.

Bautista F, Van der Lugt J, Kearns PR, Mussai FJ, Zwaan CM, Moreno L.

Expert Opin Drug Discov. 2016 Nov;11(11):1111-1122. Epub 2016 Sep 27. Review.

PMID:
27670965
13.

Neuroblastoma arginine addiction subverts the anticancer immune response.

De Santo C, Mussai F.

Oncoimmunology. 2015 Nov 11;5(2):e1078967. eCollection 2016 Feb.

14.

Molecular basis and current strategies of therapeutic arginine depletion for cancer.

Fultang L, Vardon A, De Santo C, Mussai F.

Int J Cancer. 2016 Aug 1;139(3):501-9. doi: 10.1002/ijc.30051. Epub 2016 Apr 15. Review.

15.

Adjunctive Treatment in Juvenile Nasopharyngeal Angiofibroma: How Should We Approach Recurrence?

Scholfield DW, Brundler MA, McDermott AL, Mussai F, Kearns P.

J Pediatr Hematol Oncol. 2016 Apr;38(3):235-9. doi: 10.1097/MPH.0000000000000524.

PMID:
26907644
16.

Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.

Mussai F, Egan S, Hunter S, Webber H, Fisher J, Wheat R, McConville C, Sbirkov Y, Wheeler K, Bendle G, Petrie K, Anderson J, Chesler L, De Santo C.

Cancer Res. 2015 Aug 1;75(15):3043-53. doi: 10.1158/0008-5472.CAN-14-3443. Epub 2015 Jun 8.

17.

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.

Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, U KP, Lo A, Ng M, Kearns P, Cheng P, De Santo C.

Blood. 2015 Apr 9;125(15):2386-96. doi: 10.1182/blood-2014-09-600643. Epub 2015 Feb 20.

18.

Challenges of clinical trial design for targeted agents against pediatric leukemias.

Mussai FJ, Yap C, Mitchell C, Kearns P.

Front Oncol. 2015 Jan 6;4:374. doi: 10.3389/fonc.2014.00374. eCollection 2014. Review.

19.

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.

Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, Qureshi A, Dazzi F, Vyas P, Cerundolo V.

Blood. 2013 Aug 1;122(5):749-58. doi: 10.1182/blood-2013-01-480129. Epub 2013 Jun 3.

20.

Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities.

Mussai F, De Santo C, Cerundolo V.

J Immunother. 2012 Jul;35(6):449-59. doi: 10.1097/CJI.0b013e31825be926. Review.

PMID:
22735803
21.

Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.

Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, Sharma A, Antignani A, Mussai F, Wayne A, Kreitman RJ, Pastan I.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:79-81. doi: 10.3109/10428194.2011.569961. Review.

PMID:
21599608
22.

Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy.

El-Mallawany NK, Geller L, Bollard CM, Wistinghausen B, Mussai F, Wayne AS, Alobeid B, Cairo MS.

Bone Marrow Transplant. 2011 May;46(5):759-61. doi: 10.1038/bmt.2010.176. Epub 2010 Jul 26. No abstract available.

23.

Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.

Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg SM, Wayne AS, Pastan I.

Br J Haematol. 2010 Aug;150(3):352-8. doi: 10.1111/j.1365-2141.2010.08251.x. Epub 2010 Jun 7.

PMID:
20528877
24.

Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome.

Mussai FJ, Cunningham LC, Rezvani G, Stratakis CA, Reynolds JC, Nesterova G, Henshaw RM, Levine JE, Helman LJ, Arthur DC, Kim SY.

J Pediatr Hematol Oncol. 2008 Aug;30(8):612-7. doi: 10.1097/MPH.0b013e318168f072.

25.

Thrombin injection for acute hemorrhage following angiography.

Richards T, Mussai FJ, Phillips-Hughes J, Uberoi R, Boardman P.

Cardiovasc Intervent Radiol. 2007 Jul-Aug;30(4):786-8.

PMID:
17533530
26.

Developing guidelines for medical students about the examination of patients under 18 years old.

Hope T, Frith P, Craze J, Mussai F, Chadha A, Noble D.

BMJ. 2005 Dec 10;331(7529):1384-6. No abstract available.

Supplemental Content

Loading ...
Support Center